Twist Bioscience Corp (NASDAQ:TWST) SVP Sells $336,704.94 in Stock

Twist Bioscience Corp (NASDAQ:TWST) SVP Patrick Weiss sold 14,729 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $22.86, for a total transaction of $336,704.94.

Patrick Weiss also recently made the following trade(s):

  • On Wednesday, September 18th, Patrick Weiss sold 14,728 shares of Twist Bioscience stock. The shares were sold at an average price of $29.78, for a total transaction of $438,599.84.
  • On Wednesday, September 4th, Patrick Weiss sold 14,728 shares of Twist Bioscience stock. The shares were sold at an average price of $27.66, for a total transaction of $407,376.48.
  • On Wednesday, August 21st, Patrick Weiss sold 14,730 shares of Twist Bioscience stock. The shares were sold at an average price of $30.66, for a total transaction of $451,621.80.

Shares of TWST traded down $0.11 on Monday, hitting $22.40. 203,141 shares of the stock traded hands, compared to its average volume of 222,689. The company has a market capitalization of $779.78 million and a PE ratio of -0.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 6.96 and a current ratio of 7.18. The business has a 50 day simple moving average of $27.73 and a 200 day simple moving average of $27.27. Twist Bioscience Corp has a one year low of $12.38 and a one year high of $35.95.



Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.09). The firm had revenue of $13.60 million for the quarter, compared to the consensus estimate of $12.51 million. Twist Bioscience had a negative net margin of 204.63% and a negative return on equity of 168.45%. On average, equities analysts expect that Twist Bioscience Corp will post -3.8 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in TWST. ARK Investment Management LLC bought a new stake in shares of Twist Bioscience during the second quarter valued at approximately $6,202,000. Emerald Advisers LLC increased its position in shares of Twist Bioscience by 146.5% during the second quarter. Emerald Advisers LLC now owns 579,601 shares of the company’s stock valued at $16,814,000 after acquiring an additional 344,463 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its position in shares of Twist Bioscience by 156.0% during the second quarter. Emerald Mutual Fund Advisers Trust now owns 524,093 shares of the company’s stock valued at $15,204,000 after acquiring an additional 319,373 shares in the last quarter. Swiss National Bank bought a new stake in shares of Twist Bioscience during the second quarter valued at approximately $305,000. Finally, Conestoga Capital Advisors LLC bought a new stake in shares of Twist Bioscience during the second quarter valued at approximately $276,000. 42.69% of the stock is owned by institutional investors.

Several equities research analysts recently weighed in on TWST shares. ValuEngine downgraded shares of Twist Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. Zacks Investment Research downgraded shares of Twist Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $26.55.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

See Also: Street Name

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.